Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

IMS 2023 | Advances that have been made in the molecular characterization of multiple myeloma

Mark Bustoros • 27 Sep 2023
IMS 2023
Multiple Myeloma

In this video, Mark Bustoros, MD, Weill Cornell Medicine, New York City, NY, discusses advances that have been made in the molecular characterization of multiple myeloma, including epigenetic characterization. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Mark Bustoros

The use of early ALC after BCMA CAR-T as a surrogate for CAR-T expansion, response & PFS in myeloma 3:57
The use of early ALC after BCMA CAR-T as a surrogate for CAR-T expansion, response & PFS in [...]
Mark Bustoros • 25 Sep 2024
Challenges associated with the management of extramedullary myeloma & ongoing research 2:07
Challenges associated with the management of extramedullary myeloma & ongoing research
Mark Bustoros • 25 Sep 2024
Upcoming therapeutic approaches in the R/R myeloma space 0:59
Upcoming therapeutic approaches in the R/R myeloma space
Mark Bustoros • 25 Sep 2024
Molecular characteristics associated with increased risk of disease progression in SMM 3:23
Molecular characteristics associated with increased risk of disease progression in SMM
Mark Bustoros • 27 Sep 2023

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals